Septerna posted a Q2 net loss of $13.03 million, narrowing from $24.84 million a year earlier; revenue rose to $26.75 million from $119,000.
R&D expenses climbed 58.34% to $35.13 million; G&A expenses increased 22.30% to $8.45 million.
Cash, cash equivalents, and marketable securities totaled $516.51 million at June 30, down from $548.66 million at Dec. 31.
Pipeline updates
The Phase 1 trial for SEP-479 is ongoing; observed elimination half-life of about three to four days supports once-daily dosing, and SAD/MAD data are expected in Q1 2027.
SEP-631 posted positive Phase 1 results; Septerna is rethinking development beyond a Phase 2b CSU study while advancing its TSHR program toward candidate selection.
SEPN•
